NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

"That’s what makes the findings of this study really exciting, because it did show a very significant improvement in both progression-free survival and overall survival," he said. The expert ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...